Systems Engineering Research and the Cancer Care Engineering Project Joseph F. Pekny, Ph. D. (Purdue University) Professor of Chemical Engineering Interim Head of Industrial Engineering

Cancer Care Engineering Project Leads: Pat Loehrer, MD Kenneth Wiseman Professor of Medicine Director, IU Simon Cancer Center Associate Dean of Cancer Research Indiana University School of Medicine Joe Pekny, PhD Professor of Chemical Engineering Interim Department Chair, Industrial Engineering Founder, Regenstrief Center for Healthcare Engineering Purdue University Marietta Harrison, PhD Professor of Medicinal Chemistry Associate Vice President for Research Director, Oncological Sciences Center Purdue University

Notre Dame Joins CCE

Project Funding U.S. Army Medical and Materiel Command – $2.3M – Negotiating additional award Regenstrief Foundation – $1.35M Walther Cancer Foundation – $1.8M NIH (2) and DoD (1) pending

Opportunity: Further Systematizing Cancer Care Innovation Thousands of Journal Articles, Best Practices, Landmark Studies, Rapid IT Advances, Large Amounts of Data, Systems Biology, Golden Age of Life Science Breakthrough Cures, Uneven Care, “Miracle” Patients, Policy Needs, Ongoing Opportunity for Reality to Research and Back Cancer Care Engineering Science & TechnologyCancer Care Practice

“We want to know with certainty whether the treatment protocol for a young, non-smoking mother of 3 with colon cancer will work. Today we can only tell her in terms of percentages the potential treatment effectiveness. The monthly cost is in the tens of thousands and may not be effective for her. We order it and hope.” Goal Needs Better Tool Now Needs Way to Rapidly Improve Tools Going Forward by Applying More, Advancing, and Targeting Science and Technology CCE Summary: Processing Samples, in Position to Develop First Generation Pilot Tools

Prevention & Treatment: Sample Acquisition & Analysis (Colorectal Cancer): Patient Subgroups CCE Component in Progress

Personalizing Cancer Care: The Importance of Patient Groups Clinical Trials Phase III Phase II Phase I Drug X Clinical Trials Phase III Phase II Phase I Clinical Trials Phase III Phase II Phase I Clinical Trials Phase III Phase II Phase I Clinical Trials Phase III Phase II Phase I On which patient groups does Drug X work? Patient groups are indistinguishable with respect to treatment What dosage is best?